ATHEROSCLEROSIS
===============

Cardiovascular disease (CVD) is the main cause of death in the western world and its incidence globally is on the rise. It is a multifactorial disease whereby known genetic and environmental effects account for only part of the variability in disease risk ([@B72]). Atherosclerosis is the primary cause of CVD and it is characterized by the development of an atheromatus plaque, which triggers luminal narrowing. Plaque rupture can result in myocardial infarction or ischemic stroke.

Atherosclerosis can be defined as a disturbed balance of lipid accumulation, giving rise to chronic inflammation of the arterial wall ([@B91]). Inflammation leads to the recruitment of a variety of immune cells, such as monocytes and T-cells, which lead to further inflammatory signaling and recruitment. This results in the development of a slow progressing lesion and luminal narrowing due to the accumulation of sub-endothelial low density lipoprotein (LDL) and immune cells ([@B69]).

The initiating phase of plaque development occurs as a result of injury to the endothelium, sources of which include hypercholesterolemia, hypertension, cigarette smoke, diabetes, and obesity; these are often chronic and therefore progress uninterrupted ([@B80]). This is followed by the formation of a fatty streak due to the accumulation of foam cells, which are modified macrophages ([@B39]). A mature plaque develops over time and contains a wider variety of cell types. These have a more complex structure consisting of a necrotic, lipid rich core, and a fibrous cap, the disruption of which leads to the clinical phenotypes mentioned previously ([@B47]). Immune cells are located at the edge of the cap, and upon activation express inflammatory cytokines such as IFN-γ and TNFα which induce vascular cell adhesion molecule-1 (VCAM-1) expression ([@B21]). Elevated levels of circulating cholesterol support CVD and atherosclerosis, which leads to the expression of adhesion molecules and chemokines by endothelial cells, further driving immune infiltration ([@B38]). Atherosclerotic plaques often develop at regions where the arteries branch, where blood flow is non-linear and exerts low shear stress (LSS), which upregulates inflammatory signaling and modulates miRNAs to promote inflammation and monocyte recruitment ([@B74]; [@B79]; [@B92]).

EPIGENETIC MODIFICATIONS
========================

Epigenetic mechanisms such as DNA methylation, post translational modification (PTM) of histone proteins and RNA mechanisms have been widely investigated in multiple diseases. DNA methylation occurs primarily on CpG dinucleotides and is associated with transcriptional repression through the inhibition of transcription factor binding ([@B24]; [@B29]; [@B12]; [@B98]). Key PTMs to histone proteins include acetylation, methylation, and phosphorylation. These histone modifications are carried out by various families of enzymes which determine promoter accessibility ([@B26]; [@B3]). RNA mechanisms such as non-coding RNAs (ncRNAs) have the ability to alter gene expression in a variety of ways and play regulatory roles during development, the response to stress and environmental stimuli. ncRNAs can be classified into three groups miRNAs, siRNAs, and LncRNAs ([@B65]; [@B76]; [@B50]). The role these epigenetic modifications play in atherosclerosis and plaque rupture is poorly known in comparison to the well-studied role they play in cancer.

Transgenerational epigenetic inheritance, which refers to the transmission of epigenetic modifications from one generation to the next, can affect the disease susceptibility of offspring ([@B51]; [@B84]). The mechanism behind these effects is not understood ([@B22]). However, various epidemiological and population studies have identified transgenerational effects, including modified cardiovascular risk, due to changes in food supply ([@B56]; [@B49]; [@B73]; [@B62]; [@B14]; [@B28]).

Epigenetics can be defined as "The study of mitotically and/or meiotically heritable changes in gene function that cannot be explained by changes in DNA sequence" ([@B8]). Here we deal with three well-studied epigenetic mechanisms (DNA methylation, histone modifications, and ncRNAs), which have been the focus of therapeutic intervention in CVD, through targeted drug delivery or dietary supplementation.

DNA METHYLATION
---------------

Animal models have been used to connect DNA methylation/epigenetic modifications and CVD, further suggesting the critical role of DNA methylation in the development of atherosclerosis and CVD ([@B4]; [@B11]; [@B83]). Studies suggest that altered patterns in methylation correlate with CVD ([@B15]; [@B52], [@B54]; [@B17]; [@B63]; [@B85]; [@B89]; [@B97]). Research carried out on genomic DNA isolated from human atherosclerotic lesions, has shown hypomethylation ([@B82]). Hypermethylation of atherosclerotic lesions and the promoter region of genes associated with atherosclerosis has also been identified in various genes, e.g. superoxide dismutase, estrogen receptor alpha, endothelial nitric oxide synthase, thus preventing their transcription ([@B15]; [@B58]; [@B46]; [@B100]). Methylation of the estrogen receptor B-gene has also been noted to contribute to atherosclerotic progression and is largely associated with aging ([@B52]).

HISTONE POST-TRANSLATIONAL MODIFICATIONS
----------------------------------------

A variety of PTMs have been identified to date. Key PTMs include acetylation, methylation and phosphorylation. These histone modifications are carried out by various families of enzymes which determine promoter accessibility ([@B3]). PTMs are often due to the integration of environmental cues at a cellular level and therefore have important roles in diseases related to lifestyle, diet and early life exposure. A number of studies clearly support a link between PTMs and atherosclerotic plaque vulnerability ([@B86]; [@B9]; [@B36]; [@B7]; [@B32]; [@B77]). The repression of type 1 collagen has been identified as a key step in atherogenesis, with a number of studies identifying the modulators of its repression (e.g., Sin3B) and PTMs which may result in its activation and subsequent plaque stabilization ([@B55]; [@B94]). HDAC3 is also known to be involved in plaque rupture; it was identified as the sole histone deacetylase (HDAC) upregulated in ruptured lesions. Inhibition of HDAC3 shifts the phenotype of plaque macrophages to anti-inflammatory and reduces lipid accumulation. Targeting this HDAC may decrease the likelihood of plaque rupture ([@B41])

NON-CODING RNA
--------------

The regulation of gene expression is influenced by ncRNAs, which have the ability to alter gene expression in a variety of ways and play regulatory roles during development, the response to stress and environmental stimuli. ncRNAs can be classified into three groups; miRNAs, siRNAs, and LncRNAs ([@B65]; [@B76]; [@B50]). miRNAs regulate genes from a different locus at a post transcriptional level, while siRNAs act to silence the locus from which they are derived ([@B50]). LncRNAs have multiple roles, their transcription alone can often alter the expression of nearby genes, and they also carry out essential regulatory roles ([@B96]). A number of studies have identified miRNAs and LncRNAs as key regulators in the development of atherosclerosis ([@B70]; [@B42]; [@B16]; [@B44]; [@B59],[@B60]; [@B90]).

EPIGENETIC TARGETING AGENTS
===========================

The use of drugs which target the enzymes responsible for epigenetic modifications such as DNA methyl-transferases (DNMTs) and HDACs have considerable therapeutic potential in CVD and other inflammatory disorders. CVD therapeutic targets include protein coding genes that have an already established relevance in CVD ([@B74]). Drug therapies that work via epigenetic mechanisms are largely unapproved by the FDA at present and those that are mainly target blood related disorders (see **Table [1](#T1){ref-type="table"}** below). Dual therapies are also undergoing trails whereby histone deacetylase inhibitor (HDACi) and DMNTs are combined. This is likely to be used in addition to chemotherapy and interferon treatment in cancer ([@B30]). In some cases, side effects such as toxicity and non-specific gene modulation have limited their use as cancer preventative agents ([@B102]).

###### 

Current FDA approved epigenetic drugs.

  Agent           Epigenetic mechanism   Application     Year of approval
  --------------- ---------------------- --------------- ------------------
  Vorinostat      HDAC                   CTCL            2006
  Romidepsin      HDAC                   CTCL            2009
  5-Azacytidine   DNMT                   MDS             2004
  Decitabine      DNMT                   MDS             2006
  Ruxolitinib     JAK1/2                 Myelofibrosis   2011

CTCL, cutaneous T cell lymphoma; MDS, myelodysplastic syndrome.

DNA METHYLTRANSFERASE INHIBITION
================================

Findings have highlighted that epigenetic variation and modification are widely implicated in CVD. However, the mechanism and result of these alterations remain widely unresolved. Conflicting results as to the degree of DNA methylation isolated from atherosclerotic lesions and from patient PBLs have been noted ([@B15]; [@B82]; [@B4],[@B5]; [@B17]). Hypermethylation of the promoter regions of genes associated with atherogenesis has also been observed in genes such as superoxide dismutase, further driving inflammation and atherogenesis, implicating methylation as a potential therapeutic target for the future ([@B13]; [@B75]; [@B58]; [@B57]).

HDACi
=====

SULFORAPHANE AND NUTRITIONAL EPIGENETICS
----------------------------------------

Extensive epidemiological evidence and animal studies suggest that cruciferous vegetables such as broccoli may help prevent and/or delay various inflammatory disorders. Sulforaphane \[1-isothiocyanato-4-(methylsulfinyl)-butane\] is thought to be principally responsible for the health benefits associated with cruciferous vegetables due to its activity as a histone deacetylase inhibitor ([@B71]; [@B31]). Sulforaphane acts as an indirect antioxidant to induce the expression of several enzymes via epigenetic modifications of the Nrf2 pathway, which leads to the induction of its downstream anti-oxidative stress pathway ([@B6]; [@B102]). Anti-oxidant response element (ARE) binds Nrf2 in the promoter region, resulting in the induction of a series of anti-oxidant, stress/detoxifying enzymes, and proteins, e.g., heme oxygenase-1 (HO-1), NAD(P)H dehydrogenase \[quinone\] 1 (NQO-1), uridine 5'-diphospho-glucuronosyltransferas (UGT), glutathione S-transferases (GST), ferretin, thioredoxin, thioredoxin reductase 1, and manganese superoxide dismutase (MnSOD) ([@B102]). Numerous epidemiological and animal studies support sulforaphane's role as an anti-oxidant and epigenetic modifier, suggesting that the risk of atherosclerosis and CVD could potentially be reduced by its use ([@B101]; [@B33]; [@B48]; [@B53]; [@B66]; [@B99]).

Sulforaphane has been shown to aid the suppression of inflammatory mediators such as VCAM-1 in endothelial cells, through its activation of Nrf2 and alters the physiology of vascular and inflammatory cells ([@B101]; [@B33]; [@B66]). High shear stress results in the development of athero-protected sites through activation of Nrf2. LSS does not, however, activate Nrf2 resulting in pro-inflammatory activation ([@B18]; [@B101]). Pharmacological activation of Nrf2 using sulforaphane has been show to suppress p38 activation, VCAM-1 expression and ROS production in cultured ECs and in wild type mice. Nrf2--/-- mice were unaffected by treatment with sulforaphane, indicating that the anti-inflammatory effects of Sulforaphane are Nrf2 dependent ([@B18]). This implies that inflammation at athero-susceptible regions can be reduced/prevented through sulforaphane mediated activation of Nrf2. Dietary intervention in human subjects has demonstrated that low concentrations of sulforaphane supplements can inhibit HDAC activity ([@B71]). To date sulforaphane is also known to inhibit HDAC activity in human colorectal cancer cells ([@B71]).

CURCUMIN
--------

Curcumin also offers great potential as a dietary atheroprotective agent. Curcumin was shown to reduce the extent atherosclerotic lesions and induce changes in the expression of genes involved in cell adhesion, transendothelial migration in APOE--/-- mice fed with 0.2% curcumin over 4 months ([@B20]). Oligomeric and monomeric flavonoid consumption has been demonstrated to modulate the expression of genes associated with CVD ([@B67]). These studies highlight a new angle for the treatment and prevention of CVD through the use of dietary supplements. Curcumin when packaged with sulforaphane has been suggested as a chemotherapeutic option for the treatment of pancreatic cancer ([@B45]; [@B88]).

PROTOCATECHUIC ALDEHYDE
-----------------------

Protocatechuic aldehyde (PA), an established HDACi, is a compound isolated from the aqueous extract of the root of the *Salvia miltiorrhiza* herb. It has been widely used in traditional Chinese medicine to treat various vascular diseases. There is evidence to suggest that PA can inhibit migration and proliferation of vascular smooth muscle cells ([@B68]). PA has been shown to affect the expression of adhesion molecules in human umbilical vein endothelial cells (HUVECs) stimulated with TNF-α, suggesting that PA inhibits TNF-α stimulated VCAM-1 and intercellular adhesion molecule-1 (ICAM-1) expression in these cells through a mechanism that involves NF-κB and AP-1 ([@B104]). The role of PA in myocardial ischemia and reperfusion injury has been investigated to determine its anti-inflammatory effect *in vivo* and its use as a potential therapeutic agent. The use of a rat model suggested that PA could protect the heart from myocardial ischemia and reperfusion injury by reducing myocardial infarct size and the activities of creatine kinase-MB and cardiac troponin ([@B93]). As with sulforaphane, the above studies of PA suggest the use of dietary supplements which act as HDAC inhibitors to help prevent the development and progression of atherosclerotic plaque.

miRNA BIOMARKERS AND INTERVENTIONS
==================================

Studies are currently investigating a potential link between miRNA expression profiles, plaque development, and rupture. The use of miRNAs in therapy includes organ targeted RNAi using viral vectors or synthetic RNA, and therapeutic strategies on the basis of modulation of miRNA function ([@B74]). However, challenges remain with issues such as specificity, as the 3′ UTR of a single mRNA can be targeted by multiple miRNAs. miRNAs also exert many different actions dependent on cell type; hence miRNA modulation therapies require precise cellular targeting and suitable delivery methods. For example miR-144-3p has been shown to accelerate plaque formation through the post transcriptional regulation of ABCA1. ABCA1 has a critical role in cellular cholesterol eﬄux and the formation of HDL. Inhibition of ABCA1 through miR-144-3p has been shown in THP-1 cells and in APOE--/-- mice to increase inflammatory cytokine secretion and accelerate plaque formation ([@B43]). This highlights how essential it is for appropriate miRNA targeting in atherosclerosis as one miRNA can influence multiple pathways. miRNA expression profiles are also likely to differ between atherosclerotic plaques and healthy arteries, and may provide useful markers and targets in atherosclerosis ([@B95]; [@B19]; [@B78]; [@B40]; [@B64]).

Many of the genes down regulated included those involved in the regulation of signal transduction, transcription, and vesicular transport. Those which were up regulated are thought to be involved in the key processes of atherosclerosis ([@B95]; [@B78]).

[@B19] investigated whether a unique miRNA signature was associated with plaque instability in humans. They identified five miRNAs, miR-100, miR-127, miR-145, miR-133a, and miR-133b which had altered expression levels. Expression of these miRNAs was greater in symptomatic plaques from patients with ischemic stroke, suggesting a role for miRNAs in plaque instability and rupture, but also as predictive biomarkers. Further findings implicate miRNAs such as miR-24 and miR-21 in the regulation of matrix metalloproteinase (MMPs), known to play a part in fibrous cap thinning and in turn plaque rupture ([@B27]; [@B34]). Endothelial miRNAs are likely to be selectively regulated by arterial flow conditions, particularly the combination of pro-atherogenic LSS and oxidized low-density lipoprotein (oxLDL) which induce the upregulation of miR-92a, suggesting the use of a miR-92a antagomir as a potential therapeutic option ([@B61]).

The potential future use of miRNAs in diagnosis and as treatment options remains promising, as a recent article highlights the effect of an RNAi drug ALN-PCS on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), in one of the first successful applications of RNAi therapeutics in a clinical setting ([@B1]; [@B103]; [@B37]). Treatment resulted in a mean 70% reduction in circulating PCSK9 plasma protein and a mean 40% reduction in LDL cholesterol from baseline relative to placebo ([@B37]). Anti miR-133 therapy has also been shown to reduce the progression of atherosclerosis and improve HDL function in Ldlr --/-- mice ([@B81]).

Circulating miRNAs have also attracted considerable attention as potential biomarkers, as they can be detected in blood and potentially used for the risk stratification of patients ([@B23]). Fichtlscherer et al identified four miRNAs which were reduced in patients with CAD compared to healthy controls, miR-126, miR-17, miR-92a, and miR-155. Muscle enriched miRNAs were also found to be more highly expressed in patients with CAD compared to volunteers ([@B35]; [@B87]). miRNAs are also involved in the regulation of macrophage phenotype alterations from inflammatory to anti-inflammatory, and they can be altered by shear stress ([@B10]; [@B2]; [@B25]). These studies clearly identify a correlation between miRNA expression and plaque instability. A number of considerations must also be taken into account such as whether the patients were receiving statins or other cholesterol modifying drugs, as this could alter/contribute to the miRNA expression observed by acting as epigenetic modifiers.

CONCLUSION
==========

Recent trends have seen advances in the progression of epigenetic drugs from bench to bedside, further supporting their importance as key drugs of the future. However many of the therapies targeting atherosclerotic disease remain unavailable for use in a clinical setting. Issues such as delivery of miRNAs to localized areas remain. However, we are now beginning to see the use of nanoparticles to deliver epigenetic inhibitors such as sulforaphane and ALN-PCS. The specificity of epigenetic therapies is also a consideration, as non-specific effects may result in gene activation/inhibition that may further hinder treatment. Unlike cancer, epigenetic therapy for atherosclerotic disease is still in its infancy, yet it represents a topic of great global concern as it is the main cause of death in the western world. Future directions and preventative measures may include the biomarker profiling of patients with high and low risk plaques through the use of circulating miRNAs, leading to considerable economic and health benefits.
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